Reduced CDX2 expression predicts poor overall survival in patients with colorectal cancer

Kwang Dae Hong, Dooseok Lee, Youngseok Lee, Sun Il Lee, Hong Young Moon

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The homeodomain transcription factor CDX2 directs development and maintenance of normal intestinal epithelium. However, the role of CDX2 in colorectal carcinogenesis is poorly understood. Hence, we investigated the CDX2 expression in patients with colorectal cancer and its relationship to tumor cell proliferation and differentiation and evaluated the role of this molecule as a biologic marker for the prediction of poor patient survival. We retrospectively reviewed 207 patients with colorectal cancer, with an available paraffin block, who underwent surgical resection between January 2002 and December 2004 at Korea University Guro Hospital. CDX2 expression was compared between tumor tissue and the adjacent normal mucosa using immunohistochemistry and Western blot analysis. Immunohistochemical staining for CDX2, Ki-67, and CK20 was performed in each tumor tissue. Immunohistochemistry revealed that CDX2 protein is overexpressed by colorectal cancer compared with adjacent normal mucosa (P < 0.001). In the Western blot analysis, tumor tissue showed a trend toward overexpression of CDX2 protein compared with normal mucosa (P = 0.09). CDX2 expression showed a significant direct correlation with the expression of Ki-67 and CK20 in tumor tissue (P = 0.028 and P = 0.042, respectively). Survival analysis showed that reduced CDX2 expression was statistically and significantly related to poor overall survival. Reduced CDX2 expression is associated with poor overall survival in patients with colorectal cancer and may be clinically useful as a marker for poor prognosis.

Original languageEnglish
Pages (from-to)353-360
Number of pages8
JournalAmerican Surgeon
Volume79
Issue number4
Publication statusPublished - 2013 Apr 1

Fingerprint

Colorectal Neoplasms
Survival
Mucous Membrane
Neoplasms
Western Blotting
Immunohistochemistry
Intestinal Mucosa
Survival Analysis
Korea
Paraffin
Cell Differentiation
Carcinogenesis
Biomarkers
Maintenance
Cell Proliferation
Staining and Labeling
CDX2 Transcription Factor

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)

Cite this

Reduced CDX2 expression predicts poor overall survival in patients with colorectal cancer. / Hong, Kwang Dae; Lee, Dooseok; Lee, Youngseok; Lee, Sun Il; Moon, Hong Young.

In: American Surgeon, Vol. 79, No. 4, 01.04.2013, p. 353-360.

Research output: Contribution to journalArticle

Hong, Kwang Dae ; Lee, Dooseok ; Lee, Youngseok ; Lee, Sun Il ; Moon, Hong Young. / Reduced CDX2 expression predicts poor overall survival in patients with colorectal cancer. In: American Surgeon. 2013 ; Vol. 79, No. 4. pp. 353-360.
@article{cc0fa8b3be014643b7950b0b05b1660a,
title = "Reduced CDX2 expression predicts poor overall survival in patients with colorectal cancer",
abstract = "The homeodomain transcription factor CDX2 directs development and maintenance of normal intestinal epithelium. However, the role of CDX2 in colorectal carcinogenesis is poorly understood. Hence, we investigated the CDX2 expression in patients with colorectal cancer and its relationship to tumor cell proliferation and differentiation and evaluated the role of this molecule as a biologic marker for the prediction of poor patient survival. We retrospectively reviewed 207 patients with colorectal cancer, with an available paraffin block, who underwent surgical resection between January 2002 and December 2004 at Korea University Guro Hospital. CDX2 expression was compared between tumor tissue and the adjacent normal mucosa using immunohistochemistry and Western blot analysis. Immunohistochemical staining for CDX2, Ki-67, and CK20 was performed in each tumor tissue. Immunohistochemistry revealed that CDX2 protein is overexpressed by colorectal cancer compared with adjacent normal mucosa (P < 0.001). In the Western blot analysis, tumor tissue showed a trend toward overexpression of CDX2 protein compared with normal mucosa (P = 0.09). CDX2 expression showed a significant direct correlation with the expression of Ki-67 and CK20 in tumor tissue (P = 0.028 and P = 0.042, respectively). Survival analysis showed that reduced CDX2 expression was statistically and significantly related to poor overall survival. Reduced CDX2 expression is associated with poor overall survival in patients with colorectal cancer and may be clinically useful as a marker for poor prognosis.",
author = "Hong, {Kwang Dae} and Dooseok Lee and Youngseok Lee and Lee, {Sun Il} and Moon, {Hong Young}",
year = "2013",
month = "4",
day = "1",
language = "English",
volume = "79",
pages = "353--360",
journal = "American Surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "4",

}

TY - JOUR

T1 - Reduced CDX2 expression predicts poor overall survival in patients with colorectal cancer

AU - Hong, Kwang Dae

AU - Lee, Dooseok

AU - Lee, Youngseok

AU - Lee, Sun Il

AU - Moon, Hong Young

PY - 2013/4/1

Y1 - 2013/4/1

N2 - The homeodomain transcription factor CDX2 directs development and maintenance of normal intestinal epithelium. However, the role of CDX2 in colorectal carcinogenesis is poorly understood. Hence, we investigated the CDX2 expression in patients with colorectal cancer and its relationship to tumor cell proliferation and differentiation and evaluated the role of this molecule as a biologic marker for the prediction of poor patient survival. We retrospectively reviewed 207 patients with colorectal cancer, with an available paraffin block, who underwent surgical resection between January 2002 and December 2004 at Korea University Guro Hospital. CDX2 expression was compared between tumor tissue and the adjacent normal mucosa using immunohistochemistry and Western blot analysis. Immunohistochemical staining for CDX2, Ki-67, and CK20 was performed in each tumor tissue. Immunohistochemistry revealed that CDX2 protein is overexpressed by colorectal cancer compared with adjacent normal mucosa (P < 0.001). In the Western blot analysis, tumor tissue showed a trend toward overexpression of CDX2 protein compared with normal mucosa (P = 0.09). CDX2 expression showed a significant direct correlation with the expression of Ki-67 and CK20 in tumor tissue (P = 0.028 and P = 0.042, respectively). Survival analysis showed that reduced CDX2 expression was statistically and significantly related to poor overall survival. Reduced CDX2 expression is associated with poor overall survival in patients with colorectal cancer and may be clinically useful as a marker for poor prognosis.

AB - The homeodomain transcription factor CDX2 directs development and maintenance of normal intestinal epithelium. However, the role of CDX2 in colorectal carcinogenesis is poorly understood. Hence, we investigated the CDX2 expression in patients with colorectal cancer and its relationship to tumor cell proliferation and differentiation and evaluated the role of this molecule as a biologic marker for the prediction of poor patient survival. We retrospectively reviewed 207 patients with colorectal cancer, with an available paraffin block, who underwent surgical resection between January 2002 and December 2004 at Korea University Guro Hospital. CDX2 expression was compared between tumor tissue and the adjacent normal mucosa using immunohistochemistry and Western blot analysis. Immunohistochemical staining for CDX2, Ki-67, and CK20 was performed in each tumor tissue. Immunohistochemistry revealed that CDX2 protein is overexpressed by colorectal cancer compared with adjacent normal mucosa (P < 0.001). In the Western blot analysis, tumor tissue showed a trend toward overexpression of CDX2 protein compared with normal mucosa (P = 0.09). CDX2 expression showed a significant direct correlation with the expression of Ki-67 and CK20 in tumor tissue (P = 0.028 and P = 0.042, respectively). Survival analysis showed that reduced CDX2 expression was statistically and significantly related to poor overall survival. Reduced CDX2 expression is associated with poor overall survival in patients with colorectal cancer and may be clinically useful as a marker for poor prognosis.

UR - http://www.scopus.com/inward/record.url?scp=84876127439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876127439&partnerID=8YFLogxK

M3 - Article

C2 - 23574843

AN - SCOPUS:84876127439

VL - 79

SP - 353

EP - 360

JO - American Surgeon

JF - American Surgeon

SN - 0003-1348

IS - 4

ER -